Venus Concept Stock (NASDAQ:VERO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.31

52W Range

$0.28 - $2.21

50D Avg

$0.49

200D Avg

$0.68

Market Cap

$2.20M

Avg Vol (3M)

$1.74M

Beta

0.64

Div Yield

-

VERO Company Profile


Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

304

IPO Date

Oct 12, 2017

Website

VERO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Service$3.41M$3.01M$4.19M
System$41.87M$47.91M$43.11M
Leases$20.50M$35.27M$45.09M
Product$10.56M$13.32M$13.23M

Fiscal year ends in Dec 23 | Currency in USD

VERO Financial Summary


Dec 23Dec 22Dec 21
Revenue$76.35M$99.50M$105.62M
Operating Income$-28.31M$-34.88M$-17.54M
Net Income$200.00K$-43.58M$-22.14M
EBITDA$-28.31M$-30.41M$-17.54M
Basic EPS-$-9.91$-6.10
Diluted EPS-$-9.91$-6.10

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 13, 24 | 9:39 AM
Q2 24Aug 13, 24 | 12:19 PM
Q1 24May 15, 24 | 12:00 AM

Peer Comparison


TickerCompany
AIMDAinos, Inc.
ANIKAnika Therapeutics, Inc.
OFIXOrthofix Medical Inc.
SGHTSight Sciences, Inc.
LNSRLENSAR, Inc.
SSKNSTRATA Skin Sciences, Inc.
VAPOVapotherm, Inc.
NUWENuwellis, Inc.
IRIXIRIDEX Corporation
NPCENeuroPace, Inc.
AXDXAccelerate Diagnostics, Inc.
SRDXSurmodics, Inc.
AZYOElutia Inc.
AXGNAxoGen, Inc.
BBLGBone Biologics Corporation
BJDXBluejay Diagnostics, Inc.
HSCSHeart Test Laboratories, Inc.
ESTAEstablishment Labs Holdings Inc.
INGNInogen, Inc.
CVRXCVRx, Inc.